Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Eculizumab

Nature Reviews Drug Discovery volume 6, pages 515–516 (2007)Cite this article

Abstract

Eculizumab (Soliris; Alexion), a monoclonal antibody that binds to the terminal complement protein C5, was approved by the FDA for the treatment of patients with paroxysmal nocturnal haemoglobinuria in March 2007. It is the first therapy to be approved specifically for the treatment of this rare blood disorder.

Eculizumab

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The complement cascade and eculizumab.

References

  1. Hillman, P. et al. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333, 1253–1258 (1995).

    Article  Google Scholar 

  2. Parker, C. et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106, 3699–3709 (2005).

    Article  CAS  Google Scholar 

  3. Rosse, W. F. et al. Immune-mediated hemolytic anaemia. Hematology 48–62 (2004).

    Article  Google Scholar 

  4. Matis, L. A. & Rollins, S. A. Complement specific antibodies: designing novel anti-inflammatories. Nature Med. 1, 839–842 (1995).

    Article  Google Scholar 

  5. Thomas, T. C. et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33, 1389–1401 (1996).

    Article  CAS  Google Scholar 

  6. Food and Drug Administration. FDA labelling information [online], 〈http://www.fda.gov/cder/foi/label/2007/125166lbl.pdf〉 (2007).

  7. Hillmen, P. et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350, 552–559 (2004).

    Article  CAS  Google Scholar 

  8. Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233–1243 (2006).

    Article  CAS  Google Scholar 

  9. Parker, C. J. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp. Hematol. 35, 523–533 (2007).

    Article  CAS  Google Scholar 

  10. Hill, A. et al. Blockade of intravascular hemolysis in PNH with the terminal complement inhibitor eculizumab unmasks low-level hemolysis potentially occurring through C3 opsonization. Blood 108, 290a (2006).

    Article  Google Scholar 

  11. Hillmen, P. et al. The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Blood 108, 40a (2006).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charles J. Parker is at the University of Utah School of Medicine, Salt Lake City, Utah 84132, USA. charles.parker@hsc.utah.edu,

    Charles J. Parker

  2. Santwana Kar is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. skar@uk.imshealth.com,

    Santwana Kar

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Charles J. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Santwana Kar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parker, C., Kar, S. & Kirkpatrick, P. Eculizumab. Nat Rev Drug Discov 6, 515–516 (2007). https://doi.org/10.1038/nrd2369

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2369

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing